Immunomodulation and AD – Down But Not Out

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

2013 Alzheimer's disease facts and figures

(2013)   Alzheimers & Dementia

Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia

(2013) Maike Gold et al.   Journal of Neuroinflammation

Intravenous immunoglobulin and Alzheimer’s disease: what now?

(2013) David A Loeffler   Journal of Neuroinflammation

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway

(2013) Bing Gong et al.   MOLECULAR IMMUNOLOGY

Three-year follow-up on the IVIg for Alzheimer's phase II study

(2012) Norman Relkin et al.   Alzheimers & Dementia

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy

(2012) Gilda Shayan et al.   ELECTROPHORESIS

Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease

(2012) Lakshman Puli et al.   Journal of Neuroinflammation

Naturally Occurring Autoantibodies against  -Amyloid: Investigating Their Role in Transgenic Animal and In Vitro Models of Alzheimer's Disease

(2011) R. Dodel et al.   JOURNAL OF NEUROSCIENCE

The projected effect of risk factor reduction on Alzheimer's disease prevalence

(2011) Deborah E Barnes et al.   LANCET NEUROLOGY

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

(2010) Richard Dodel et al.   DRUGS

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

(2010) Johanna Magga et al.   Journal of Neuroinflammation

Amyloid-β Oligomers: Possible Roles as Key Neurotoxins in Alzheimer's Disease

(2010) Alex L. Lublin et al.   MOUNT SINAI JOURNAL OF MEDICINE

Antibody concentrations to Aβ1–42 monomer and soluble oligomers in untreated and antibody–antigen-dissociated intravenous immunoglobulin preparations

(2009) Andrea C. Klaver et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction

(2009) Jennifer L. Tomic et al.   NEUROBIOLOGY OF DISEASE

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

(2009) H. Fillit et al.   NEUROLOGY

Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake

(2009) Shaomin Li et al.   NEURON

Natural human antibodies to amyloid beta peptide

(2008) Paul Szabo et al.   AUTOIMMUNITY REVIEWS

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

(2008) Ganesh M Shankar et al.   NATURE MEDICINE

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING